[{"id":"8f439945-e5eb-40b9-a7e6-6eb64cdd7790","acronym":"","url":"https://clinicaltrials.gov/study/NCT01409161","created_at":"2021-01-18T05:47:46.957Z","updated_at":"2025-02-25T17:35:27.084Z","phase":"Phase 2","brief_title":"Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT01409161","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • Vesanoid (tretinoin) • arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 151","initiation":"Initiation: 10/05/2011","start_date":" 10/05/2011","primary_txt":" Primary completion: 12/18/2025","primary_completion_date":" 12/18/2025","study_txt":" Completion: 12/18/2025","study_completion_date":" 12/18/2025","last_update_posted":"2025-01-28"},{"id":"dfbc062f-ed24-4f40-8bd7-edd7973cf532","acronym":"","url":"https://clinicaltrials.gov/study/NCT04919369","created_at":"2021-06-10T01:52:31.476Z","updated_at":"2024-07-02T16:35:14.922Z","phase":"Phase 1","brief_title":"All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04919369","lead_sponsor":"Dwight Owen","biomarkers":" PD-L1 • ALK","pipe":"","alterations":" ","tags":["PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Vesanoid (tretinoin)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 10/18/2021","start_date":" 10/18/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-13"},{"id":"2aab645e-82e6-4871-a584-636d0a665d5d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04897490","created_at":"2021-05-21T11:52:52.627Z","updated_at":"2024-07-02T16:35:24.138Z","phase":"","brief_title":"RWE of 1st Line Treatment With ATO/ATRA for Adult APL","source_id_and_acronym":"NCT04897490","lead_sponsor":"Grupo Argentino de Tratamiento de la Leucemia Aguda","biomarkers":" BCR","pipe":" | ","alterations":" FLT3 mutation","tags":["BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vesanoid (tretinoin) • arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 03/01/2021","start_date":" 03/01/2021","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-01-09"},{"id":"df5b5086-1697-4c00-8ecc-c22d551b5706","acronym":"","url":"https://clinicaltrials.gov/study/NCT02339740","created_at":"2021-01-18T11:07:04.205Z","updated_at":"2024-07-02T16:35:28.404Z","phase":"Phase 3","brief_title":"Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT02339740","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3 • RARA • PML","pipe":" | ","alterations":" FLT3 mutation • FLT3 wild-type","tags":["FLT3 • RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • mitoxantrone • Vesanoid (tretinoin) • arsenic trioxide • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 158","initiation":"Initiation: 07/21/2015","start_date":" 07/21/2015","primary_txt":" Primary completion: 10/31/2020","primary_completion_date":" 10/31/2020","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2023-11-22"},{"id":"3212545e-61a5-4679-863b-11a4f4ec1221","acronym":"ATRA","url":"https://clinicaltrials.gov/study/NCT04113863","created_at":"2021-01-18T20:06:42.396Z","updated_at":"2024-07-02T16:35:32.515Z","phase":"Phase 2","brief_title":"Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer","source_id_and_acronym":"NCT04113863 - ATRA","lead_sponsor":"Mario Negri Institute for Pharmacological Research","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anastrozole • Vesanoid (tretinoin)"],"overall_status":"Recruiting","enrollment":" Enrollment 112","initiation":"Initiation: 06/18/2019","start_date":" 06/18/2019","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-10-19"},{"id":"9c2e3fcc-0c2c-452d-b5c3-1b136e0e84cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05016349","created_at":"2021-08-23T12:52:57.566Z","updated_at":"2024-07-02T16:36:25.993Z","phase":"Phase 3","brief_title":"Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.","source_id_and_acronym":"NCT05016349","lead_sponsor":"Mahmoud Ramadan mohamed Elkazzaz","biomarkers":" KRT5","pipe":"","alterations":" ","tags":["KRT5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Vesanoid (tretinoin) • Epidiolex (cannabidiol) • Mifeprex (mifepristone)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2021-08-23"},{"id":"e5587414-ede2-4832-a20e-9bd4ff957340","acronym":"","url":"https://clinicaltrials.gov/study/NCT03031249","created_at":"2021-01-18T14:55:11.899Z","updated_at":"2024-07-02T16:36:47.929Z","phase":"Phase 1/2","brief_title":"Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia","source_id_and_acronym":"NCT03031249","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" NPM1","pipe":" | ","alterations":" NPM1 mutation","tags":["NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Vesanoid (tretinoin) • arsenic trioxide"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 02/08/2017","start_date":" 02/08/2017","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-03-20"}]